Fostering Collaboration to Accelerate Discoveries

The NYGC has built a unique scientific ecosystem for multi-institutional collaborations in genomic research. Leveraging our strengths and expertise in collaboration, sequencing at scale, genomic analysis, and technology development, we advance novel approaches and partnerships beyond that possible for any single institution to gain insights into the biological drivers and molecular mechanisms of disease, with the goal of advancing the practice of precision medicine.”

Tom Maniatis, PhD Evnin Family Scientific Director & CEO Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics, Columbia University

Studying the changes in gene expression we see in each stage of ALS is key to identifying what triggers symptom onset. Our work with Target ALS ensures we maintain productive collaborations with ALS researchers to develop life-changing treatments.”

Read more on NYGC’s work with Target ALS and New York State.

Hemali Phatnani Director, Center for Genomics of Neurodegenerative Disease, NYGC Assistant Professor of Neurological Sciences (in Neurology), Columbia University

The ability to leverage data generated in a different lab and even processed with a different method, to then use it to link individuals in a completely different anonymous dataset, is rather striking and highlights a real privacy issue for single-cell data. We aim for this study to help quantify risks before data release and shape the design of future studies to ensure greater privacy for patients.”

Gamze Gürsoy, PhD Core Faculty Member, NYGC Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University

Decoding causality is fundamental to providing interpretable quantitative explanations of elements of the non-coding genome in cancer. Biological problems of this nature require cross-cutting programs where investigators with a broad range of expertise are supported to collaborate and focus on building new measurement methods and computational frameworks to understand the complex dynamics of cancer biology.”

Samuel Aparicio, BM, BCh, PhD, FRCPath, FRSC Senior Scientific Director of Cancer Genomics, NYGC Chair of Molecular Oncology, UBC/BC Cancer Agency